Cheng Yangyang, Du Xiaohui, Zhang Bilin, Zhang Junxia
Department of Endocrinology, Central Theater Command General Hospital of the Chinese People's Liberation Army, Wuhan, 430070, Hubei, China.
Exp Clin Endocrinol Diabetes. 2022 Apr;130(4):248-253. doi: 10.1055/a-1474-8220. Epub 2021 Apr 30.
Serum wnt1-induced signaling pathway protein 1 (WISP1) levels are increased with obesity, which is a common complication associated with lower extremity atherosclerotic disease (LEAD). However, to date, the relationship between elevated WISP1 levels and the incidence of lower extremity atherosclerotic disease (LEAD) in type 2 diabetes mellitus (T2DM) remains unclear.
174 newly diagnosed type 2 diabetic patients were enrolled in our study. Patients were divided into two groups, LEAD group (n=100) and control group (n=74). Anthropometric parameters, blood pressure and some biochemical parameters were obtained. Body composition was detected by bioelectrical impedance analysis (BIA). Levels of serum insulin were determined by radioimmunoassay. Serum WISP1 and interleukin 6 (IL-6) levels were determined using an enzyme-linked immunosorbent assay.
It was shown that serum WISP1 levels in diabetic patients with LEAD were higher than those without LEAD (<0.001). Serum WISP1 levels were positively related with waist circumference (=0.237, 0.003), waist-hip ratio (0.22, 0.006), visceral fat area (0.354, <0.001), serum creatinine (0.192, 0.012), interleukin 6 (0.182, 0.032), c-reactive protein (0.681, P<0.001), triglycerides (0.119, <0.001), fasting glucose (0.196, 0.011), glycated hemoglobin (0.284, <0.001), and HOMA-IR (0.285, <0.026). Compared with the lowest tertile, the odds ratio of the middle tertile for LEAD incidence was 3.27 (95% CI, 1.24-8.64) and 4.46 (95% CI, 1.62-12.29) for the highest tertile after adjusting confounding factors.
The results suggest that increased serum WISP1 levels independently contribute to the incidence of LEAD in patients with newly diagnosed T2DM.
血清Wnt1诱导信号通路蛋白1（WISP1）水平随肥胖增加，肥胖是下肢动脉粥样硬化疾病（LEAD）的常见并发症。然而，迄今为止，2型糖尿病（T2DM）患者中WISP1水平升高与下肢动脉粥样硬化疾病（LEAD）发病率之间的关系仍不清楚。
174例新诊断的2型糖尿病患者纳入本研究。患者分为两组，LEAD组（n = 100）和对照组（n = 74）。获取人体测量参数、血压和一些生化参数。通过生物电阻抗分析（BIA）检测身体成分。采用放射免疫分析法测定血清胰岛素水平。使用酶联免疫吸附测定法测定血清WISP1和白细胞介素6（IL-6）水平。
结果显示，患有LEAD的糖尿病患者血清WISP1水平高于未患LEAD的患者（<0.001）。血清WISP1水平与腰围（=0.237，P = 0.003）、腰臀比（0.22，P = 0.006）、内脏脂肪面积（0.354，<0.001）、血清肌酐（0.192，P = 0.012）、白细胞介素6（0.182，P = 0.032）、C反应蛋白（0.681，P<0.001）、甘油三酯（0.119，<0.001）、空腹血糖（0.196，P = 0.011）、糖化血红蛋白（0.284，<0.001）和HOMA-IR（0.285，<0.026）呈正相关。与最低三分位数相比，校正混杂因素后，中间三分位数发生LEAD的比值比为3.27（95%CI，1.24 - 8.64），最高三分位数为4.46（95%CI，1.62 - 12.29）。
结果表明，血清WISP1水平升高独立导致新诊断的T2DM患者发生LEAD。
